Another instance is entinostat, a synthetic benzamide derivative HDAC inhibitor that selectively inhibits class I and IV HDAC enzymes.1342 Entinostat has been evaluated in several phase II trials in patients with breast cancer and has improved patient median OS (NCT00676663). The gene discussed is HDAC9; the disease is breast carcinoma.